Audience Unimpressed By Verve’s Base Playing
Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.
You may also be interested in...
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
The Swiss major’s CFO Harry Kirsch told Scrip that US cardiologists are slowly but surely getting to grips with the 'buy-and-bill' reimbursement model for Leqvio, while EU sales are not going to grow significantly until cardiovascular outcomes data read out in a few years’ time.